Article
Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele.
Cancer research - 15 Aug 2011
Virgili Anna, Koptyra Mateusz, Dasgupta Yashodhara, Glodkowska-Mrowka Eliza, Stoklosa Tomasz, Nacheva Elisabeth P, Skorski Tomasz
Abstract excerpt
Chronic myeloid leukemia in chronic phase (CML-CP) cells that harbor oncogenic BCR-ABL1 and normal ABL1 allele often become resistant to the ABL1 kinase inhibitor imatinib. Here, we report that loss of the remaining normal ABL1 allele in these tumors, which results from cryptic interstitial deletion in 9q34 in patients who did not achieve a complete cytogenetic remission (CCyR) during treatment, engenders a novel...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.